↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Craft Alan) srt2:(2015)"

Search: WFRF:(Craft Alan) > (2015)

Result 1-2 of 2

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Gaspar, Nathalie, et al. (author) Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. 2015 In: Journal of Clinical Oncology. - 1527-7755. ; 33:27, s. 140-3036 Research review (peer-reviewed)abstract Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists. Successive first-line trials addressed the efficacy of various cyclic combinations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used to tailor therapies. The role of high-dose chemotherapy is still debated. Current 5-year overall survival for patients with localized disease is 65% to 75%. Patients with metastases have a 5-year overall survival < 30%, except for those with isolated pulmonary metastasis (approximately 50%). Patients with recurrence have a dismal prognosis. The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies. Current options and future approaches will be discussed.
2.	van den Berg, Henk, et al. (author) Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. 2015 In: European Journal of Cancer. - : Elsevier BV. - 1879-0852 .- 0959-8049. ; 51:16, s. 2453-2464 Journal article (peer-reviewed)abstract Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-2 of 2

Refine your search

Type of publication: journal article (1); research review (1)

Type of content: peer-reviewed (2)

Author/Editor: Hjorth, Lars (2); Le Deley, Marie-Ceci ... (2); Brennan, Bernadette (2); Whelan, Jeremy (2); Judson, Ian (2); Juergens, Heribert (2); show more...; Paulussen, Michael (2); Dirksen, Uta (2); Marec-Berard, Perrin ... (2); Gaspar, Nathalie (2); Claude, Line (1); Ladenstein, Ruth (1); Picci, Piero (1); Brichard, Bénédicte (1); Kühne, Thomas (1); Gelderblom, Hans (1); Sundby Hall, Kirsten (1); van den Berg, Henk (1); Ferrari, Stefano (1); Grimer, Robert (1); Delattre, Olivier (1); Craft, Alan (1); Kruseova, Jarmila (1); Le Teuff, Gwénaël (1); Wheatley, Keith (1); Oberlin, Odile (1); Hawkins, Douglas S. (1); Luksch, Roberto (1); Lewis, Ian J (1); Kovar, Heinrich (1); van den Berg, Hendri ... (1); Michon, Jean (1); Bernstein, Mark L (1); Craft, Alan W (1); Womer, Richard B (1); Ladenstein, Ruth Lyd ... (1); show less...

University: Lund University (2)

Language: English (2)

Research subject (UKÄ/SCB): Medical and Health Sciences (2)

Year: 2015 (2)Undo refine

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view